CClinicalTrials.gg
CompletedNCT02958046Updated Nov 8, 2016

The Efficacy of Lansoprazole and Domperidone Combination on Intragastric and Intraesophageal Acidity

A Phase 4 interventional study of Lansoprazole/Domperidone in Gastroesophageal Reflux Disease, sponsored by Neutec Ar-Ge San ve Tic A.Ş. Completed at 1 site in Turkey. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2016-11-08.

Sponsored by Neutec Ar-Ge San ve Tic A.Ş · Phase 4, Interventional, and Treatment

Phase
Phase 4
Study type
Interventional
Enrollment
12
Allocation
Not applicable
Ages
18 Years to 65 Years
Sex
All
01

Study summary

The purpose of this study is to investigate the efficacy of lansoprazole combination with domperidone on intragastric acidity and intraesophageal acidity, GERD symptoms, impedance kinetics, gastric emptying in patients with gastroesophageal reflux disease (GERD).

Read the detailed description

Objectives of the trial to assess the efficacy of lansoprazole in combination with domperidone on gastric acidity, intraesophageal acidity, GERD symptoms, impedance kinetics and gastric emptying in patients with GERD.

24 hour pH measurement and gastric emptying test will be done at screening visit and after 7 days of drug treatment. Twelve patients will take one tablet for 7 days.

02

Conditions studied

  • Gastroesophageal Reflux Disease
03

In context

Gastroesophageal Reflux

1,067 studies on the registry are indexed under Gastroesophageal Reflux; 188 are open to participants now.

This study's enrollment of 12 is below the median of 72 across 712 interventional studies indexed under Gastroesophageal Reflux.

Browse Gastroesophageal Reflux studies →

Lead sponsor

Neutec Ar-Ge San ve Tic A.Ş is the lead sponsor of 20 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Diagnosis of GERD with symptoms (i.e. regurgitation, pyrosis) during last one year with at least 1 or more episodes a week
  • Age ≥ 18 years and \<65 years
  • Helicobacter pylori (an infection) negative
  • Have a body mass index (BMI) between 18 and 33 kg/m²
  • pH>4 gastric exposure \<25% on a 24-hour dual pH channel monitoring study performed prior to screening (normal intragastric pH +2SD)
  • Pathologic intraesophageal acidity exposure (DeMeester score >14.75 and/or >4% of pH\<4 (at least 21 hours measured)

Exclusion criteria

Exclusion Criteria:

  • Have food existence at stomach during upper GIS endoscopy, Barrett's stricture, GIS bleeding, malignite, and all type of GIS pathology to affects the study
  • Have allergy to the study drug or any of the excipients of the formulation
  • Must use of pain relieving medications (NSAIDs) during study, (paracetamol not excess of 2 gram/day can be used)
  • Use of any concomitant therapy which are drug affects the motility of GIS and acid secretion
  • Use of prostaglandin analogs and sucralfate
  • Have taken PPIs or H2-blockers within 7 days and prokinetic drugs within 3 days before entering the study
  • History of surgery of cholecystectomy
  • Abusing drugs or alcohol
  • Have a major psychiatric disease
  • Use of antidepressant (patient with minor depression or under controlled with drug can be included)
  • Have suppressed immune system or taken a immunosupressive treatment, including cortisone.
  • Have malabsorption, gastric outlet obstruction that affects the absorption of drug
  • Must use of drug ketoconazole, iron salts, digoxin, ampicilin esters , anticoagulants, antineoplastic agents
  • Women who are pregnant or of childbearing
  • Have gastroparesis
  • Current or a history of cancer, with the exception of fully excised skin carcinoma (Malign Melanoma will be excluded).
  • Have severe concomitant disease (i.e. uncontrolled or insuline dependent diabetes mellitus, symptomatic bladder stone (patients have asemptomatic, not undergone colesistit, stone \<3cm and polib \<1cm can be included), active or unhealed gastric or duodenum ulcer, Zollinger Ellison syndrome, primary esophageal motility disorder, pancreatitis, inflammatory bowel disease, chronic hepatic disease, severe lung disease, uncontrolled kidney failure, cardiac failure, cerebrovascular disease, epilepsy) which affects the conduct and result of study.
05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
12 participants (actual)

Study arms

  • Experimental
    Lansoprazole/Domperidone

    DUOLANS 30/30 mg SR tablet per oral, one tablet daily

    Drug: Lansoprazole/Domperidone

Interventions

  • DrugLansoprazole/Domperidone

    DUOLANS 30/30 mg SR tablet per oral, one tablet daily

    Also known as: Duolans

06

What researchers measure

Primary outcomes

  1. The percentage time of 24-hour intragastric pH >4 compared to baseline

    Time frame: 7 days

  2. The AUC of 24-hour intragastric pH >4 compared to baseline

    Time frame: 7 days

Secondary outcomes

  1. The significant increase in total measurements of median pH

    Time frame: 7 days

  2. The significant increase in nocturnal measurements of median pH

    Time frame: 7 days

  3. The decrease in reflux symptom index calculated by weekly regurgitation numbers

    Time frame: 7 days

  4. The decrease in reflux symptom index calculated by weekly pyrosis numbers

    Time frame: 7 days

  5. The percentage time of 24-hour intragastric pH >2 compared to baseline

    Time frame: 7 days

  6. The percentage time of 24-hour intragastric pH >6 compared to baseline

    Time frame: 7 days

  7. The AUC of 24-hour intragastric pH >2 compared to baseline

    Time frame: 7 days

  8. The AUC of 24-hour intragastric pH >6 compared to baseline

    Time frame: 7 days

  9. The percentage time of 24-hour total intragastric pH >4 compared to baseline

    Time frame: 7 days

  10. The AUC of 24-hour total intragastric pH >4 compared to baseline

    Time frame: 7 days

  11. The evaluation of gastric emptying by octanoic acid breath test compared to baseline

    Time frame: 7 days

  12. The evaluation of safety of study drug (Number of Participants with Abnormal Laboratory Values and/or Adverse Events That Are Related to Treatment)

    Time frame: 7 days

07

Study locations

1 site
  • Department Of Gastroenterology, Faculty Of Medicine, Ege University, Izmir, Turkey
    İzmir, Turkey
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Nov 8, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02958046
Lead sponsor
Neutec Ar-Ge San ve Tic A.Ş
Responsible party
Sponsor
First posted
Nov 8, 2016
Start date
Jan 2014
Primary completion
May 2015
Completion
Aug 2015
Last update
Nov 8, 2016

Study contacts

Neutec Ar-Ge San ve Tic A.S
study director · Neutec Ar-Ge Clinical Trial

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion